Coya Therapeutics Inc (COYA)

Currency in USD
6.08
-0.02(-0.33%)
Closed·
COYA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
COYA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.876.23
52 wk Range
4.6510.24
Key Statistics
Prev. Close
6.1
Open
6.15
Day's Range
5.87-6.23
52 wk Range
4.65-10.24
Volume
14.78K
Average Volume (3m)
58.95K
1-Year Change
2.35%
Book Value / Share
2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
COYA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.64
Upside
+173.73%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Coya Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Coya Therapeutics Inc Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease. In addition, the company’s pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Compare COYA to Peers and Sector

Metrics to compare
COYA
Peers
Sector
Relationship
P/E Ratio
−5.9x−1.6x−0.5x
PEG Ratio
0.32−0.060.00
Price/Book
3.0x3.2x2.6x
Price / LTM Sales
27.5x9.7x3.3x
Upside (Analyst Target)
147.7%203.9%43.4%
Fair Value Upside
Unlock9.7%7.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 16.64
(+173.73% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.44 / -0.46
Revenue / Forecast
200.00K / --
EPS Revisions
Last 90 days

COYA Income Statement

People Also Watch

12.0600
INKT
-4.74%
4.120
ATAI
-0.72%
3.45
ALT
-2.13%
49.91
AKRO
-1.08%

FAQ

What Stock Exchange Does Coya Therapeutics Trade On?

Coya Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Coya Therapeutics?

The stock symbol for Coya Therapeutics is "COYA."

What Is the Coya Therapeutics Market Cap?

As of today, Coya Therapeutics market cap is 102.02M.

What Is Coya Therapeutics's Earnings Per Share (TTM)?

The Coya Therapeutics EPS (TTM) is -1.08.

When Is the Next Coya Therapeutics Earnings Date?

Coya Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is COYA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Coya Therapeutics Stock Split?

Coya Therapeutics has split 0 times.

How Many Employees Does Coya Therapeutics Have?

Coya Therapeutics has 8 employees.

What is the current trading status of Coya Therapeutics (COYA)?

As of 08 Aug 2025, Coya Therapeutics (COYA) is trading at a price of 6.08, with a previous close of 6.10. The stock has fluctuated within a day range of 5.87 to 6.23, while its 52-week range spans from 4.65 to 10.24.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.